How semaglutide works to lose weight — and what it actually does inside your body

The biggest myth: semaglutide simply suppresses your appetite like a diet pill

Most people assume semaglutide cuts hunger the way a strong cup of coffee might, a short-term, stimulant-style blunting that wears off by lunchtime. That framing is wrong, and it matters, because it shapes whether someone understands why gradual dose increases are necessary and why stopping abruptly tends to reverse results.

What semaglutide actually does is imitate GLP-1 (glucagon-like peptide-1), a hormone your gut releases naturally after eating. GLP-1 travels to the brain's hypothalamus and signals satiety; it also acts on the vagus nerve and slows gastric emptying, so food stays in the stomach longer. Semaglutide is engineered to resist the enzyme that normally breaks GLP-1 down within minutes, giving it a half-life of roughly a week, which is why a single weekly injection can maintain this hormonal signal continuously. The NHS medicines information on semaglutide explains this mechanism clearly for patients.

The result is not willpower on demand. It is a recalibration of the hormonal signals that govern how hungry you feel and how satisfied a meal leaves you. People often describe it as the background noise of constant hunger simply going quiet. That is a physiological change, not a psychological one.

What the clinical evidence actually shows for weight loss with semaglutide

A question our prescribers hear most weeks is whether the trial results apply to ordinary people or only to tightly controlled study participants. It is fair scepticism. The STEP 1 trial enrolled 1,961 adults with obesity or overweight plus at least one weight-related condition, all without type 2 diabetes, and followed them for 68 weeks. Participants using semaglutide 2.4 mg achieved an average body-weight reduction of around 15%, compared with roughly 2.4% in the placebo group, a meaningful real-world signal, not a laboratory artefact.

For context on how semaglutide compares to other licensed options, the mechanism and outcomes of Wegovy are covered in more depth elsewhere on this site. What is worth noting here is that results varied across the trial population (some people lost more, some less) and the people who combined treatment with consistent dietary and activity changes tended to see the greater end of that range. Semaglutide creates the hormonal conditions for eating less; it does not replace the lifestyle component.

The 15% average figure is the one cited by NICE in its appraisal of semaglutide (TA875). NICE recommends semaglutide for weight management within specialist services for up to two years, for adults meeting specific BMI and comorbidity criteria. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. You can read the NICE appraisal of semaglutide (TA875) in full.

How the dose schedule shapes the way semaglutide works in practice

Semaglutide for weight loss is not taken at a fixed dose from day one. The Wegovy titration schedule runs from 0.25 mg up through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, with roughly four weeks at each step. The purpose of that gradual increase is tolerability: the GI side effects that most people experience (nausea, loose stools, reflux) are dose-dependent and tend to ease as the body adjusts. Starting low and climbing slowly is what makes the higher therapeutic doses manageable for most people.

The 2.4 mg weekly injection is where the primary weight-loss effect is established. In April 2026 the MHRA also approved a higher 7.2 mg single-dose pen, with trial data showing an average weight reduction of around 20.7% at that dose, approaching the results seen with tirzepatide. If you want a practical guide to making the most of Wegovy treatment, including what to eat alongside it, that page covers the lifestyle context in detail.

Side effects are largely gastrointestinal: nausea is the most common, particularly after a dose increase, and typically settles within a couple of weeks. Constipation, diarrhoea and indigestion are also reported. Seek urgent medical attention for any severe, persistent abdominal pain that radiates to the back, this can be a sign of pancreatitis, which the MHRA flagged in a 2026 Drug Safety Update as an infrequent but serious risk with GLP-1 medicines. These are all reasons why treatment runs under ongoing prescriber oversight rather than as a one-off purchase.

Who semaglutide is licensed for, and what the consultation is actually checking

Semaglutide for weight management is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea or cardiovascular disease. BMI is the starting point, not the whole picture. A prescriber also reviews your medical history, current medicines, and any contraindications before approving treatment. Semaglutide is not recommended during pregnancy, whilst breastfeeding, or if you are trying to conceive; it is not licensed for under-18s.

It is also worth knowing that Ozempic contains the same active ingredient but carries a different licence, it is authorised for type 2 diabetes management, not weight loss. Wegovy is the product licensed specifically for weight management in the UK. If you are researching your options more broadly, the semaglutide overview page covers licensing, the difference between Wegovy and Ozempic, and what to expect. For a side-by-side look at whether semaglutide is effective for weight loss based on published evidence, that page goes further into the data.

Private treatment through a regulated UK pharmacy means no referral and no waiting list, subject to clinical suitability. At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers, not software. If you are based in Northern Ireland and want to understand local access routes, our semaglutide Belfast page covers what is available in the city. Check your eligibility with our prescribers, the consultation is free.